These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 38697230)

  • 1. Are biologics effective on lung hyperinflation in patients with resistant asthma?
    Goto T; Hernandez CG; Tsujimoto Y; Kitagawa T
    Respir Med; 2024 Jun; 227():107652. PubMed ID: 38697230
    [No Abstract]   [Full Text] [Related]  

  • 2. Are biologics effective on lung hyperinflation in patients with resistant asthma? A reply.
    Cazzola M; Maniscalco M
    Respir Med; 2024 Jun; 227():107653. PubMed ID: 38679339
    [No Abstract]   [Full Text] [Related]  

  • 3. Severe T2-high asthma in the biologics era: European experts' opinion.
    Pavord I; Bahmer T; Braido F; Cosío BG; Humbert M; Idzko M; Adamek L
    Eur Respir Rev; 2019 Jun; 28(152):. PubMed ID: 31285291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe Eosinophilic Allergic Asthma Responsive to Mepolizumab After Failure of 2 Consecutive Biologics.
    Sánchez-Jareño M; Barranco P; Romero D; Domínguez-Ortega J; Quirce S
    J Investig Allergol Clin Immunol; 2019 Feb; 29(1):79-81. PubMed ID: 30785114
    [No Abstract]   [Full Text] [Related]  

  • 5. Biologics for paediatric severe asthma: trick or TREAT?
    Saglani S; Bush A; Carroll W; Cunningham S; Fleming L; Gaillard E; Gupta A; Murray C; Nagakumar P; Paton J; Roberts G; Seddon P; Sinha I
    Lancet Respir Med; 2019 Apr; 7(4):294-296. PubMed ID: 30824361
    [No Abstract]   [Full Text] [Related]  

  • 6. Selection of Biologics in Severe Asthma: A Multifaceted Algorithm.
    Dávila I; Quirce S; Olaguibel JM
    J Investig Allergol Clin Immunol; 2019; 29(4):325-328. PubMed ID: 30969172
    [No Abstract]   [Full Text] [Related]  

  • 7. Molecular Targets for Biological Therapies of Severe Asthma.
    Pelaia C; Crimi C; Vatrella A; Tinello C; Terracciano R; Pelaia G
    Front Immunol; 2020; 11():603312. PubMed ID: 33329598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Personalized medicine with biologics for severe type 2 asthma: current status and future prospects.
    Godar M; Blanchetot C; de Haard H; Lambrecht BN; Brusselle G
    MAbs; 2018 Jan; 10(1):34-45. PubMed ID: 29035619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biologics in pediatric lung disease.
    McGhee SA
    Curr Opin Pediatr; 2018 Jun; 30(3):366-371. PubMed ID: 29538045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Asthma biologics: Underuse, overuse, and best use?
    Rank MA; Oppenheimer JJ
    Ann Allergy Asthma Immunol; 2019 Apr; 122(4):358-359. PubMed ID: 30578858
    [No Abstract]   [Full Text] [Related]  

  • 11. Biologic agents licensed for severe asthma: a systematic review and meta-analysis of randomised controlled trials.
    Kyriakopoulos C; Gogali A; Markozannes G; Kostikas K
    Eur Respir Rev; 2024 Apr; 33(172):. PubMed ID: 38657997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biologics in Asthma: Emerging Biologics.
    Desai B; Adrish M; Mohan A; Lugogo NL
    Immunol Allergy Clin North Am; 2024 Nov; 44(4):751-763. PubMed ID: 39389722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biologics in severe asthma: Which one, When and Where?
    Rupani H; Murphy A; Bluer K; Renwick C; McQuitty P; Jackson DJ; Heaney LG; Chaudhuri R; Menzies-Gow A; Calvert J; Siddiqui S
    Clin Exp Allergy; 2021 Sep; 51(9):1225-1228. PubMed ID: 34289191
    [No Abstract]   [Full Text] [Related]  

  • 14. Biologics, Clinical Context, and the Asthmas.
    Casale TB; Israel E
    J Allergy Clin Immunol Pract; 2019; 7(5):1437-1439. PubMed ID: 31076059
    [No Abstract]   [Full Text] [Related]  

  • 15. Severe asthma and biologics: Data are good, listening to patients is better.
    Bukstein DA; Guerra DG
    Ann Allergy Asthma Immunol; 2021 Sep; 127(3):285-286. PubMed ID: 34479728
    [No Abstract]   [Full Text] [Related]  

  • 16. Real-Life effects of benralizumab on exacerbation number and lung hyperinflation in atopic patients with severe eosinophilic asthma.
    Pelaia C; Busceti MT; Crimi C; Carpagnano GE; Lombardo N; Terracciano R; Vatrella A; Pelaia G
    Biomed Pharmacother; 2020 Sep; 129():110444. PubMed ID: 32593131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Obesity influences the outcomes of anti-IgE (omalizumab) therapy of asthma.
    Gu C; Upchurch K; Mamaril-Davis J; Wiest M; Lanier B; Millard M; Turner J; Joo H; Oh S
    Clin Exp Allergy; 2020 Oct; 50(10):1196-1199. PubMed ID: 32585057
    [No Abstract]   [Full Text] [Related]  

  • 18. Promises and challenges of biologics for severe asthma.
    Tan R; Liew MF; Lim HF; Leung BP; Wong WSF
    Biochem Pharmacol; 2020 Sep; 179():114012. PubMed ID: 32389637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Understanding the response to asthma biological therapy.
    Roberts G
    Clin Exp Allergy; 2020 Sep; 50(9):992-993. PubMed ID: 32902035
    [No Abstract]   [Full Text] [Related]  

  • 20. [INTRODUCTION AND SELECTION OF BIOLOGICS FOR PEDIATRIC ASTHMA].
    Tezuka J
    Arerugi; 2021; 70(5):359-365. PubMed ID: 34275991
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.